Comparison between 150 mg monthly and 5 mg daily risedronate in postmenopausal osteoporosis; Effects on bone quality and bone remodelling
Pascale Chavassieux(Hôpital Edouard Herriot), Robert R. Recker(Creighton University), Rachelle Eusebio(Procter & Gamble (United States)), Ivo Valter(Vähiuuringute Tehnoloogia Arenduskeskus), Nathalie Portero(Inserm), Shaonan Xu(Procter & Gamble (United States)), P.D. Delmas(UConn Health), José Zanchetta(Universidad del Salvador)
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k